Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B round brings $48.2mm to Karyopharm; $19mm added

Executive Summary

Karyopharm Therapeutics Inc. (nuclear transport modulators for cancer) plans to use the $48.2mm raised through a Series B round to fund clinical trials of its KPT330, a Phase I compound for advanced, relapsed, or refractory blood and solid tumors. An undisclosed private investor led the round, and was joined by additional buyers including Delphi Ventures, which takes a seat on Karyopharm's board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies